永安藥業(002365.SZ):子公司與加拿大健美生經銷合作期屆滿及簽訂中國區域產品銷售轉讓條款説明書
格隆匯11月3日丨永安藥業(002365.SZ)公佈,公司於2022年11月3日召開第六屆董事會第十二次會議,審議通過了《關於控股子公司與加拿大健美生經銷合作期屆滿及簽訂<中國區域產品銷售轉讓條款説明書>的議案》,同意公司控股子公司美深(武漢)貿易有限公司(“武漢美深”)與加拿大健美生(英文名:JAMIESON LABORATORIES LTD.,“加拿大健美生”)、健美生保健產品(上海)有限公司(“健美生上海”;“健美生上海”與“加拿大健美生”一併,以下統稱“健美生”)簽訂《中國區域產品銷售轉讓條款説明書》,將武漢美深與加拿大健美生簽署的經銷協議到期日從2022年12月31日延長至2023年3月31日,經銷協議期滿後,加拿大健美生基於自身全球戰略的需要收回武漢美深在中國大陸經營健美生產品的專營權,並對武漢美深幾年來在中國區域內銷售運營健美生產品時形成的有形和無形資產進行回購,為此在滿足相關條件的前提下,向武漢美深支付如下款項:
(1)加拿大健美生累計支付895萬加元,其中775萬加元為武漢美深交接資產轉讓及過渡期提供的總體支持款項,120萬加元為武漢美深提供的過渡支持服務款項;(2)健美生以“淨成本”向武漢美深回購滿足條件的健美生品牌庫存產品,具體金額以“資產轉讓日”雙方認可的庫存清單計算為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.